These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35774424)

  • 1. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
    Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
    Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving Immunotherapy Into Early-Stage Lung Cancer.
    Linehan A; Forde PM
    Cancer J; 2020; 26(6):543-547. PubMed ID: 33298726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
    Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
    World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
    Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.
    Wu X; Chau YF; Bai H; Zhuang X; Wang J; Duan J
    Front Oncol; 2022; 12():1099304. PubMed ID: 36761426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
    Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
    Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.
    Guo H; Li W; Qian L; Cui J
    Chin J Cancer Res; 2021 Apr; 33(2):203-215. PubMed ID: 34158740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
    Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].
    Shu C; Zhu D; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.